Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities
Posted Oct 20 2011 8:00pm
Description of Invention: Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin and ability to fold proteins correctly. This application claims a B. anthracis strain in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield.
Applications:
Vaccine production
Recombinant protein production
B. anthracis vaccine production
Advantages:
Highly efficient production of recombinant proteins
Low cost production of recombinant proteins
Development Status:
Early-stage
In vitro data available
Inventors: Andrei P Pomerantsev (NIAID) Stephen H Leppla (NIAID)
Collaborative Research Opportunity: The NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize B. anthracis vaccines, B. anthracis protein production. For collaboration opportunities, please contact Charles Rainwater at 301-435-8617.
For Licensing Information Please Contact: Peter Soukas J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 14, Rockville, MD 20852-3804 United States Email: soukasp@mail.nih.gov Phone: 301-435-4646 Fax: 301-402-0220
Description of Invention:
Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin and ability to fold proteins correctly. This application claims a B. anthracis strain in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield.
Applications:
Advantages:
Development Status:
Inventors:
Andrei P Pomerantsev (NIAID)
Stephen H Leppla (NIAID)
Patent Status:
HHS, Reference No. E-202-2011/0
US, Application No. 61/514,384 filed 02 Aug 2011
US, Application No. 61/521,617 filed 09 Aug 2011
Relevant Publication:
Collaborative Research Opportunity:
The NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize B. anthracis vaccines, B. anthracis protein production. For collaboration opportunities, please contact Charles Rainwater at 301-435-8617.
For Licensing Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Email: soukasp@mail.nih.gov
Phone: 301-435-4646
Fax: 301-402-0220
Ref No: 2330
Updated: 10/2011